

Oryzon to Present at 4th CHI X-Gen Congress, Epigenetics, Targets and Therapies on March 6

Barcelona, January 24th, 2012. Oryzon a Biopharmaceutical company dedicated to the discovery of biomarkers and development of novel therapeutics and diagnostics announced today that Dr. Tamara Maes, will present at the 4th Annual CHI X-Gen Congress, in the CLINICAL GENOMICS. Epigenetics, Targets and Therapies: on March 5-7 March at the Hilton San Diego Resort in San Diego, California

Barcelona, January 24th, 2012. Dr. Maes's presentation will occur on March 6th at 11:00 am. Under the title "Development of Novel, Potent LSD1 Inhibitors and Their In Vitro and In Vivo Effects on Tumor Cell Growth", she will present the features of developed enantiomerically pure, potent and selective LSD1 inhibitors that are >1000x stronger than parnate, highly selective over related enzymes MAO-A/B, have excellent pharmacological characteristics and are active in vivo at doses of down to 0.05mpk. Other relevant aspects as the in vitro selectivity profile of our LSD1 inhibitors as well as the in vitro and in vivo response to LSD1 inhibition using FACS, IHQ, ChIP, and genome wide expression analysis will be discussed. She will finally report on the efficacy of LSD1 in different cancer xenograft models.

The *TARGET AND THERAPIES* session will be chaired by Dr Andrew Pope, Group Director of the Technology & Science Platform of GlaxoSmithKline who will give an Overview of Current and Developing Approaches to The Discovery of New Chemical Matter which Modulates Epigenetic Targets. In the same session, the Directors of Biology of Epizyme and Constellation Pharmaceuticals, two other companies active in the Epigenetic field, together with researchers from the Harvard Medical School will also present other interesting aspects of the field.

Epigenetics is a hot spot field in the pharmaceutical industry. It is predicted that world revenues for epigenetic therapies and technologies will reach \$2.73bn in 2015 and that the overall market will grow with a CAGR of 16% between 2010 and 2015. Therapies will remain the largest source of revenue in the epigenetics market. The deal activity on the field is intense.

Oryzon Genomics, is the global leader in Histone Lysine Demethylases with a special emphasis on Lysine Specific Demethylases (LSD1 and LSD2). LSD1 is a flavin dependent amine oxidase

capable of selective demethylation Lys-4 of histone H3. LSD1 has been proposed as a target for oncology, viral diseases and neurodegeneration. Oryzon has a wide drug-discovery program on LSD1 with around 800 compounds. According to Carlos Buesa, C.E.O. of the company. *“Oryzon’s compounds are by far the most potent inhibitors described, much more active than those of competitors. The company has a very strong patent position with 20 patent applications and we are glad to communicate to the Epigenetic community our progresses and the potential of LSD1 as therapeutic target”*

About Oryzon

Founded in 2000, Oryzon (www.oryzon.com) has one of the most complete technological platforms for biomarker identification in Europe. With a strong specialization in genomics, proteomics and bioinformatics, the company identifies biomarkers for a variety of neoplastic and neurodegenerative diseases. The company has a powerful platform for biomarker and target validation which includes technologies such as RNAi, microarrays, phage display and a structural genomic platform with a fragment screening approach (NMR and X ray crystallography). Oryzon develops new drugs and monoclonal antibodies against targets identified in its biomarker discovery programs but also develops diagnostic products.

GynEC®-DX is a good example of the Diagnostic activity of the company. This product was discovered after 5 years of intense research. It is a signature of 5 genes differentially expressed that are highly accurate to determine cancer status in uterine aspirates and when combined with pathology on aspirates has a Negative predictive value of 99,6% according to the results obtained in a recent multi-centric double blind prospective study. Commercialization of this product that has been developed jointly with Laboratorios Reig-Jofré is expected in 1Q 2012.

Other launches under way

Oryzon entered into a partnership in the field of molecular diagnostics with New Zealand firm Pacific Edge Ltd in 2011. According to the agreement, Oryzon holds an exclusive license to market the Cxbladder assay, which detects bladder cancer in urine in some European countries. Oryzon will run the Cxbladder test in its Clinical Analysis Lab, which was authorized by the Catalanian Government last year. *“The central lab is the axis and launching platform of our diagnostic and personalized medicine division”*, explains Carlos Buesa. *“We have shown that our biomarker discovery platform is capable of developing personalized medicine products and bringing them to market. The goal is to become the leader in molecular diagnostics in Spain and to partner our therapeutic programs with specialized pharmaceutical companies.*

For further information, please contact:

Carlos Buesa
Chief Executive Officer
Tel. +34 93 515 13 13,
cbuesa@oryzon.com

Emili Torrell
Business Development Officer
Tel. +34 93 515 13 13,
etorrell@oryzon.com